Business Daily from THE HINDU group of publications
Friday, Apr 13, 2007
ePaper
Business Daily from THE HINDU group of publications Friday, Apr 13, 2007 ePaper |
|
|
|
|
|
|
|
Corporate
-
Announcements
Our Bureau
New Delhi April 12 Ranbaxy Laboratories said it has received marketing approval to sell Cefprozil in Canada. The approval from Health Canada is for tablets in two dosages (250 mg and 500 mg) and for Cefprozil powder for oral suspension (250mg/5ml). The company has sized the Canadian market for the drug at more than Rs 106 crore (C$28.2 million). The antibiotic is used in the treatment of upper respiratory tract infections, and uncomplicated skin and urinary tract infections. "We are pleased to receive these approvals for RAN - Cefprozil tablets and powder for oral suspension to expand the number of product offerings that Ranbaxy commercialises for use by patients who require the therapeutic benefits of this product where indicated," said Mr Bill Abboud, President, Ranbaxy Pharmaceuticals Canada Inc (RPCI). Based in Ontario, Canada, the sales and distribution company is a wholly owned subsidiary of Ranbaxy Pharmaceuticals. In December, last year, the Gurgaon based pharma company had received US FDA approval for two strengths of the generic version Bristol Myers Squibb's Cefzil. Two months ago, Hyderabad based Aurobindo Pharma, also announced US FDA approval for two strengths of oral suspension of Cefprozil.
More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|